<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>734883_111</messagenumb>
		<messagesenderidentifier>LILLYFDA</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151008</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>3</safetyreportversion>
		<safetyreportid>US-ELI_LILLY_AND_COMPANY-US201201004141</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130125</transmissiondate>
		<reporttype>1</reporttype>
		<serious>2</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20120106</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130114</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>US-ELI_LILLY_AND_COMPANY-US201201004141</companynumb>
		<linkedreport>
			<linkreportnumb>US201108008319</linkreportnumb>
		</linkedreport>
		<linkedreport>
			<linkreportnumb>US201210008601</linkreportnumb>
		</linkedreport>
		<primarysource>
			<reportertitle>Dr.</reportertitle>
			<reportergivename>Tim</reportergivename>
			<reporterfamilyname>Boersma</reporterfamilyname>
			<reporterstreet>501 South Grace Street</reporterstreet>
			<reportercity>Addison</reportercity>
			<reporterstate>IL</reporterstate>
			<reporterpostcode>60101</reporterpostcode>
			<reportercountry>US</reportercountry>
			<qualification>1</qualification>
		</primarysource>
		<primarysource>
			<reportertitle>Ms.</reportertitle>
			<reportergivename>Carla</reportergivename>
			<reporterfamilyname>Hoeft</reporterfamilyname>
			<reporterstreet>839 Lockwood Circle</reporterstreet>
			<reportercity>Naperville</reportercity>
			<reporterstate>IL</reporterstate>
			<reporterpostcode>60563</reporterpostcode>
			<reportercountry>US</reportercountry>
			<qualification>5</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>Eli Lilly and Company</senderorganization>
			<senderdepartment>BS200</senderdepartment>
			<sendertitle>Mr.</sendertitle>
			<sendergivename>John</sendergivename>
			<sendermiddlename>A.</sendermiddlename>
			<senderfamilyname>Fredenburg</senderfamilyname>
			<senderstreetaddress>Lilly Corporate Center</senderstreetaddress>
			<sendercity>Indianapolis</sendercity>
			<senderstate>IN</senderstate>
			<senderpostcode>46285</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>2770207</sendertel>
			<sendertelcountrycode>317</sendertelcountrycode>
			<senderfax>8666441697</senderfax>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>Food and Drug Administration - CDER</receiverorganization>
			<receiverdepartment>Office of Surveillance and Epidemiology</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>12300 TwinbrookParkway, Suite 240</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20851</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3017709299</receivertel>
			<receivertelcountrycode>001</receivertelcountrycode>
			<receiverfax>3017706614</receiverfax>
			<receiverfaxcountrycode>001</receiverfaxcountrycode>
			<receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>CH</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19510531</patientbirthdate>
			<patientweight>81.633</patientweight>
			<patientheight>168</patientheight>
			<patientsex>2</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Cerebrovascular accident</patientepisodename>
				<patientmedicalstartdateformat>610</patientmedicalstartdateformat>
				<patientmedicalstartdate>201103</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
				<patientmedicalcomment>affected left side, only had use of one arm and one leg; handicap</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Diabetes mellitus</patientepisodename>
				<patientmedicalstartdateformat>610</patientmedicalstartdateformat>
				<patientmedicalstartdate>201103</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>normal blood sugars range 110-120 but they have been 150-180</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Hyperglycemia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hyperglycaemia</reactionmeddrapt>
				<termhighlighted>2</termhighlighted>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201112</reactionstartdate>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>lack of drug effect</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Lack of drug effect</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Drug ineffective</reactionmeddrapt>
				<termhighlighted>2</termhighlighted>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201112</reactionstartdate>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>HUMALOG LISPRO</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugbatchnumb>A867101A</drugbatchnumb>
				<drugauthorizationnumb>20-563</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Eli Lilly and Company</drugauthorizationholder>
				<drugstructuredosagenumb>48</drugstructuredosagenumb>
				<drugstructuredosageunit>025</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>48 u, qd</drugdosagetext>
				<drugdosageform>Injection</drugdosageform>
				<drugadministrationroute>058</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Diabetes mellitus</drugindication>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>201105</drugstartdate>
				<actiondrug>6</actiondrug>
				<activesubstance>
					<activesubstancename>INSULIN, LISPRO</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hyperglycaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hyperglycaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>HUMALOG LISPRO</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>20-563</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Eli Lilly and Company</drugauthorizationholder>
				<drugseparatedosagenumb>3</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>UNK, tid</drugdosagetext>
				<drugdosageform>Injection</drugdosageform>
				<drugadministrationroute>058</drugadministrationroute>
				<actiondrug>6</actiondrug>
				<activesubstance>
					<activesubstancename>INSULIN, LISPRO</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hyperglycaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hyperglycaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>This spontaneous case, reported by a physician who contacted the company to report a product complaint, concerns a 59 year old Caucasian female patient. 

Medical history included a stroke in Mar-2011, followed by a diagnosis of diabetes during that hospitalization. The stroke affected her left side and she only had use of one arm and one leg. The patient reported at follow-up she was handicap following the stroke. Concomitant medication were not provided.

The patient began using insulin lispro (Humalog) via a disposable KwikPen device beginning on an unspecified date, subcutaneously, dosed by sliding scale three times daily, 48 units a day for the treatment of diabetes. It was reported the patient initiated insulin lispro during hospitalization following her stroke. Upon follow-up, the physician stated insulin lispro was started in May-2011. On 06-Dec-2011, seven months after initiating insulin lispro, the patient received a new box of KwikPen devices and had been having a difficult time with them. While using these pens her blood sugar was between 150 and 180 when her normal blood sugar range was 110 to 120 (units not provided) (product complaint 12003795/ Lot A867101A for the box). The patient changed to a new box of pens and her blood sugar was then controlled (resolved). The patient was not hospitalized due to the event. The physician reported the diagnosis as hyperglycemia and ineffective control. Insulin lispro continued.

It was not provided if the patient was a trained user of the device. A friend of the patient who was a physician helped her. The general device duration of use was not provided. The duration of use of the box of suspect devices was about one month. Use of KwikPen device continued via a new box of pens. Return status of the suspect devices was unknown.

The physician thought that the event of increased blood glucose was very likely related to insulin lispro because it was bad and not stored properly before purchase. The physician thought the lack of drug effect was related to the insulin lispro because the increased blood glucose resolved after the patient got a new package. 

Update 16-Jan-2012: Information received on 06-Jan-2012 was determined to be new clinical episode to US201108008319. All information regarding new clinical episode has been added to this case. Patient link to case US201108008319.

Update 06-Feb-2012: Additional information received from the physician on 03-Feb-2012. Added patients race, weight, and height. Added start date of insulin lispro. Added physicians opinion of relatedness and diagnosis. Case and narrative updated with new information accordingly.

Update 14-Feb-2012: Upon review removed start date of May-2011 that was provided by the physician as it preceded the patients stroke. Case and narrative updated accordingly.

Update 24-Jan-2013: Additional information was received on 14-Jan-2013 from the reporting physician and from the patient. Patient reporter was added; phone number was added to patient information; medical history of stroke and diabetes was added with dates; start date of insulin lispro was added back to case from previous follow-up; serious event of stroke was removed; case was downgraded to non-serious and case narrative was updated to reflect additional information provided.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
